Results 171 to 180 of about 22,516 (228)
Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?
Annals of Oncology, 2012 The introduction of early PSa-based diagnosis has profoundly impacted the epidemiology of castration-resistant prostate cancer (CRPC). Many patients enter the disease at an early stage when the only sign of resistance to androgen deprivation therapy (ADT) is a progressive elevation of prostate-specific antigen (PSA).
Bertrand Tombal
exaly +4 more sources
Molecular Interplay between AURKA and SPOP Dictates CRPC Pathogenesis via Androgen Receptor
Cancers, 2020 SPOP, an adaptor protein for E3 ubiquitin ligase can function as a tumor-suppressor or a tumor-enhancer. In castration-resistant prostate cancer (CRPC), it inhibits tumorigenesis by degrading many oncogenic targets, including androgen receptor (AR ...
Kavita Shah, Asif Raza, Asif Raza
exaly +2 more sources
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
Cancer Biology and Therapy, 2012 The current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure.
Amelia Altavilla +2 more
exaly +4 more sources
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics [PDF]
Cancer and Metastasis Reviews, 2014 With five novel therapies shown to improve survival in metastatic castration-resistant prostate cancer (CRPC) in the last 3 years, patients are now living longer and experiencing better quality of life.
Deborah Mukherji +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drug Resistance of Enzalutamide in CRPC
Current Drug Targets, 2018Understanding and targeting the mechanisms of resistance to enzalutamide in castration resistant prostate cancer.Enzalutamide (MDV3100, XTANDI) is a second generation androgen receptor inhibitor that is designed for the treatment of castration-resistant prostate cancer (CRPC) and has prolonged survival time.
Xuedong, Chen +3 more
openaire +2 more sources
Enzalutamide treatment for the whole spectrum of CRPC
Nature Reviews Urology, 2018The FDA recently expanded the indication for enzalutamide for the treatment of all men with metastatic and nonmetastatic castration-resistant prostate cancer on the basis of the PROSPER trial. Now that both disease states can have the same treatment, the need to thoroughly identify metastatic lesions is questioned.
Hanson, Zhao, Stephen, Freedland
openaire +2 more sources
Second-generation antiandrogens in nonmetastatic CRPC
Nature Reviews Urology, 2018The FDA recently approved the second-generation antiandrogen apalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer on the basis of metastasis-free survival data from the SPARTAN trial. However, whether apalutamide is clinically superior to enzalutamide and whether early or late treatment is preferable remains to ...
Robert Chandler, Johann de Bono
openaire +2 more sources
2018
Prostate cancer (PC) is the second most common cause of cancer-related mortality in US men, and 180,890 of new PC cases occurred in 2016 [1]. At the time of diagnosis, approximately 12% of patients had locally advanced PC, and about 4% of patients had PC with metastasis [2].
Yoon Seok Suh, Jae Young Joung
openaire +1 more source
Prostate cancer (PC) is the second most common cause of cancer-related mortality in US men, and 180,890 of new PC cases occurred in 2016 [1]. At the time of diagnosis, approximately 12% of patients had locally advanced PC, and about 4% of patients had PC with metastasis [2].
Yoon Seok Suh, Jae Young Joung
openaire +1 more source